At the in vitro,cellular, and animal levels, our pilot work has confirmed the effectivenessof IPP1 as a direct inhibitor of tau aggregation, providing a leadcompound and even an innovative design strategy of drug developmenttargeting the intrinsically disordered peptide chain in protein misfoldingdiseases, such as AD. Here, MAPT is linked to Alzheimer disease.